Hal Barron

On 1 August 2022, Hal transitioned from his previous role to a Non-Executive Director, with additional responsibilities to support R&D.

Hal was previously Chief Scientific Officer and President, R&D at GSK from 1 January 2018 until his appointment as a Non-Executive Director. He was also an Executive Director of the GSK Board of Directors and a member of the GSK Leadership Team.

Prior to joining GSK, Hal was President, R&D at Calico LLC (California Life Company), an Alphabet-funded company that uses advanced technologies to increase understanding of lifespan biology. Hal was a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation. Hal previously served as a Non-Executive Board Director of GRAIL, Inc and an Advisory Board Member of Verily Life Sciences LLC.

Prior to this, Hal was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer.

He holds a Bachelor of Science degree in Physics from Washington University in St Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.

Hal has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.